Letter by Moris et al Regarding Article, “Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the work by Jones et al1 evaluating the efficiency of ticagrelor as an antithrombotic regimen for long-term management in patients with symptomatic peripheral artery disease (PAD) with a history of limb revascularization. Despite overwhelming data demonstrating the efficacy of antiplatelet therapy in heart disease and stroke, data in PAD are still scarce. Aspirin has modest evidence supporting a reduction in cardiovascular events in patients with PAD, whereas clopidogrel monotherapy may be more effective in PAD. Ticagrelor is beneficial in patients with acute coronary syndrome and prior myocardial infarction without solid …